Skip to main content
SpringerLink
Log in

Cardiovascular Effects and Risk of Syncope Related to Donepezil in Patients with Alzheimer’s Disease

  • Original Research Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Background: When otherwise unexplained, syncope in patients with Alzheimer’s disease may be attributed to bradycardia caused by cholinesterase inhibitors. We studied prospectively the clinical events and cardiovascular changes occurring during treatment with donepezil in patients with Alzheimer’s disease.

Methods: Consecutive patients presenting with mild-to-moderate Alzheimer’s disease were included in the study. Their clinical characteristics, blood pressure, heart rate and electrocardiogram were recorded before (baseline) and during treatment with donepezil. The drug was administered at a dosage of 5 mg/day for 1 month and 10 mg/day for the following 7 months, as tolerated. We compared the baseline observations with those made at 1, 2 and 8 months of donepezil treatment. We also examined the effects of negatively chronotropic or dromotropic drugs concomitantly administered with donepezil.

Results: Thirty patients were included in the study, of whom 43% were taking negatively chronotropic or dromotropic drugs. The first month of therapy (donepezil 5 mg/day) was completed by 26 patients. During the 7-month high-dosage phase (10 mg/day), four patients dropped out of the study; thus, 22 patients completed the full 8 months of the study.

The mean heart rate was 66 ± 8 beats/min at baseline in the overall study population. This decreased significantly to 62 ± 9, 61 ± 7 and 62 ± 8 beats/min at the 1, 2 and 8 month timepoints, respectively (all p = 0.002 vs baseline). Among patients not receiving negatively chronotropic or dromotropic drugs, heart rate decreased significantly over the course of the study (from 67 ± 8 beats/min at baseline to 62 ± 8 beats/min at 1 month, 62 ± 7 beats/min at 2 months and 62 ± 8 beats/min at 8 months [all p = 0.005 vs baseline]). There was no significant change in heart rate in patients who were receiving negatively chronotropic or dromotropic drugs.

The PR interval increased over the course of the study in all patient groups, but these changes were only statistically significant in the group of patients who were not taking negatively chronotropic or dromotropic drugs (155 ± 23ms at baseline vs 158 ± 21, 160 ± 22 and 163 ± 24ms at the 1, 2 and 8 month timepoints; all p = 0.02 vs baseline).

One patient developed syncope due to orthostatic hypotension; there were no cases of bradycardia-induced syncope. Gastrointestinal manifestations were reported in ten of the study patients. Abdominal pain and vomiting were the reasons for study termination in five of the eight patients who did not complete the trial.

Conclusion: A donepezil-induced decrease in heart rate and increase in PR interval were observed only in patients with Alzheimer’s disease who were not treated with negatively chronotropic or dromotropic drugs. These changes were not associated with bradycardia-induced syncope.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Fox PJ, Kohatsu N, Max W, et al. Estimating the costs of caring for people with Alzheimer disease in California: 2000–2040. J Public Health Policy 2001; 22: 88–97

    Article  PubMed  CAS  Google Scholar 

  2. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S10–5

    PubMed  CAS  Google Scholar 

  3. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S4–9

    Article  PubMed  CAS  Google Scholar 

  4. Wolfson C, Wolfson DB, Asgharian M, et al. Clinical Progression of Dementia Study Group. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001; 344: 1111–6

    CAS  Google Scholar 

  5. Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer’s disease. Drugs 2001; 61: 41–52

    Article  PubMed  CAS  Google Scholar 

  6. Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer’s disease. Am J Health Syst Pharm 1997; 54: 2805–10

    PubMed  CAS  Google Scholar 

  7. Calvo-Romero JM, Ramos-Salado JL. Symptomatic sinus bradycardia associated with donepezil. Rev Neurol 1999; 28: 1070–2

    PubMed  CAS  Google Scholar 

  8. Shepherd G, Klein-Schwartz W, Edwards R. Donepezil overdose: a tenfold dosing error. Ann Pharmacother 1999; 33: 812–5

    Article  PubMed  CAS  Google Scholar 

  9. Morganroth J, Graham S, Hartman R, et al. Electrocardiographic effects of rivastigmine. J Clin Pharmacol 2002; 42: 558–68

    Article  PubMed  CAS  Google Scholar 

  10. Mant T, Troetel WM, Imbimbo BP. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. J Clin Pharmacol 1998; 38: 610–7

    PubMed  CAS  Google Scholar 

  11. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000; 57: 94–9

    Article  PubMed  CAS  Google Scholar 

  12. Bordier P, Garrigue S, Barold SS, et al. Significance of syncope in patients with Alzheimer’s disease treated with cholinesterase inhibitors. Europace 2003; 5: 429–31

    Article  PubMed  CAS  Google Scholar 

  13. Brembilla-Perrot B, Regent MC, Hanesse B, et al. Paroxysmal atrioventricular block due to anticholinesterase therapy. [in French]. Arch Mal Coeur Vaiss 2004; 97: 1265–7

    PubMed  CAS  Google Scholar 

  14. Jane Newby V, Anne Kenny R, McKeith IG. Donepezil and cardiac syncope: case report. Int J Geriatr Psychiatry 2004; 19: 1110–2

    Article  PubMed  Google Scholar 

  15. Bordier P, Lanusse S, Garrigue S, et al. Causes of syncope in patients with Alzheimer’s disease treated with donepezil. Drugs Aging 2005; 22: 687–94

    Article  PubMed  CAS  Google Scholar 

  16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th rev. ed. (DSM IV). Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  17. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984; 34: 939–44

    Article  PubMed  CAS  Google Scholar 

  18. Kenny RA, Shaw FE, O’Brien JT, et al. Carotid sinus syndrome is common in dementia with Lewy bodies and correlates with deep white matter lesions. J Neurol Neurosurg Psychiatry 2004; 75: 966–71

    Article  PubMed  CAS  Google Scholar 

  19. Senard JM, Brefel-Courbon C, Rascol O, et al. Orthostatic hypotension in patients with Parkinson’s disease: pathophysiology and management. Drugs Aging 2001; 18: 495–505

    Article  PubMed  CAS  Google Scholar 

  20. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1996; 46: 1470

    Article  Google Scholar 

  21. Rees SA, Curtis MJ. Tacrine inhibits ventricular fibrillation induced by ischaemia and reperfusion and widens QT interval in rat. Cardiovasc Res 1993; 27: 453–8

    Article  PubMed  CAS  Google Scholar 

  22. Savci V, Gurun MS, Cavun S, et al. Cardiovascular effects of centrally injected tetrahydroaminoacridine in conscious normotensive rats. Eur J Pharmacol 1998; 346: 35–41

    Article  PubMed  CAS  Google Scholar 

  23. Fitzpatrick AP, Lee RJ, Epstein LM, et al. Effect of patient characteristics on the yield of prolonged baseline head-up tilt testing and the additional yield of drug provocation. Heart 1996; 76: 406–11

    Article  PubMed  CAS  Google Scholar 

  24. McLaren AT, Allen J, Murray A, et al. Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord 2003; 15: 183–8

    Article  PubMed  CAS  Google Scholar 

  25. Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease: a 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000; 11: 299–313

    Article  CAS  Google Scholar 

  26. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269–76

    CAS  Google Scholar 

  27. Blass JP, Cyrus PA, Bieber F, et al. Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group. Alzheimer Dis Assoc Disord 2000; 14: 39–45

    Article  CAS  Google Scholar 

  28. Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope: update 2004. Eur Heart J 2004; 6: 467–537

    Article  Google Scholar 

  29. Pavri BB, Ho RT. Syncope: identifying cardiac causes in older patients. Geriatrics 2003; 58: 26–31

    PubMed  Google Scholar 

  30. Kenny RA. Syncope in the elderly: diagnosis, evaluation, and treatment. J Cardiovasc Electrophysiol 2003; 14: S74–7

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Cardiovascular Hospital of Haut-Leveque, Avenue de Magellan, Bordeaux-Pessac, 33604, France

    Philippe Bordier, Stephane Garrigue, Stephane Lanusse, Julien Margaine, Frederic Robert, Laurent Gencel & Alexia Lafitte

Authors
  1. Philippe Bordier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephane Garrigue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephane Lanusse
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Julien Margaine
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frederic Robert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Laurent Gencel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alexia Lafitte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philippe Bordier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bordier, P., Garrigue, S., Lanusse, S. et al. Cardiovascular Effects and Risk of Syncope Related to Donepezil in Patients with Alzheimer’s Disease. CNS Drugs 20, 411–417 (2006). https://doi.org/10.2165/00023210-200620050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200620050-00005

Keywords

Search

Navigation